Minerva Neurosciences (NERV) Payables (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Payables data on file, last reported at $2.1 million in Q1 2026.

• Quarterly Payables rose 231.0% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 231.0% YoY) and the FY2025 annual result came in at $639707.0, down 60.21% from the prior year.
• Payables rose to $2.1 million in Q1 2026, from $639707.0 in the prior quarter.
• In the past five years, Payables ranged from a high of $2.1 million in Q1 2026 to a low of $298251.0 in Q2 2023.
• A 5-year average of $1.1 million and a median of $960998.0 in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables slumped 80.37% — and 2026, when it soared 231.0%.
• Tracing NERV's Payables over 5 years: stood at $969667.0 in 2022, then soared by 86.18% to $1.8 million in 2023, then fell by 10.94% to $1.6 million in 2024, then slumped by 60.21% to $639707.0 in 2025, then jumped by 231.12% to $2.1 million in 2026.
• The last three Payables figures came in at $2.1 million (Q1 2026), $639707.0 (Q4 2025), and $944492.0 (Q3 2025), per Business Quant data.